stiinte med 3 2011.indd - Academia de Ştiinţe a Moldovei

Ştiinţe Medicale
Indiferent de rezultatele studiilor, fumatul nu va fi recomandat
bolnavilor cu CU, deoarece efectul asupra
bolii se nivelează de acţiunea nefavorabilă asupra sistemelor
cardiovascular şi respirator.
Totalizând cele expuse, putem presupune că factorii
de mediu, asociaţi cu BII, posibil, îşi exercită acţiunea
prin intermediul florei intestinale (spre exemplu,
particularităţile alimentaţiei, factorii igienici etc.)
şi al sistemului imun, iar dereglările florei intestinale
şi ale statutului imun la persoanele cu susceptibilitate
genetică conduc spre apariţia inflamaţiei cronice în
intestin.
Concluzii. Interacţiunile dintre susceptibilitatea
genetică, caracterul atacului antigenic al microflorei
intestinale şi caracterul răspunsului imun la această
agresiune antigenică sunt mecanisme complexe
şi necesită studiere în continuare. În mod schematic
aceste legături sunt reprezentate în figura 2. Caracterul
şi particularităţile acestor interacţiuni, probabil,
determină nu doar apariţia BII, dar şi fenotipul bolii,
exprimat prin varianta clinico-evolutivă.
Bibliografie selectivă
1. Lakatos P. Environmental factors affecting infl ammatory
bowel disease: have we made progress? In: Dig.
Dis., 2009, 27(3), p. 215-225.
2. Kaser A., Zeissig S., Blumberg R. Genes and environment:
how will our concepts on the pathophysiology
of IBD develop in the future? In: Dig. Dis., 2010, 28(3), p.
395-405.
3. Fiocchi C. The multifactorial pathogenesis of IBD.
Inflam. bowel disease – Diagnostic and therapeutic strategies.
Falk Symposium 154. Moscow, 2006, p. 21-22.
4. Kirsner J.B., Spencer J.A. Family occurrence of
ulcerative colitis, regional enteritis, and ileocolitis. In:
Ann. Intern. Med., 1963,; 59, p. 133-144.
5. Jewell D.P. Genetic basis of infl ammatory bowel
disease. Inflammation in the intestinal tract: pathogenesis
and treatment. Falk symp. 169, 2009, Kiev, p. 17-19.
6. Hugot J.P., Laurent-Puig P, Gower-Roussean C. et
al. Mapping of a susceptibility locus for Crohn’s disease on
chromosome 16. In: Nature, 1996; 379(6), p. 821-822.
7. Hugot J.P., Chamaillard M., Zouali H. et al. Association
of NOD2 leucine-rich repeat variants with susceptibility
to Crohn’s disease. In: Nature, 2001, 411(4), p.
599-603.
8. Ogura Y., Inohara N., Benito A. et al. NOD2, a
NOD1-Apaf-1 family member that is restricted to monocytes
and activates NF-kB. In: J. Biol. Chem., 2001, 276,
p. 4812-4818.
9. Duer R.H. Genome-wide association studies herald
a new era of rapid discoveries in inflammatory bowel disease
research. In: Gastroenterol., 2007, 132, p. 2045-2062.
10. Cho J.H., Weaver C.T. The genetics of infl ammatory
bowel disease. In: Gastroenterol. 2007, 133, p. 1327-
1339.
11. Satsangi J., Parkes M., Louis E. et al. Two stage
genome-wide search in infl ammatory bowel disease provides
evidence for susceptibility loci on chromosomes 3, 7
and 12. In: Nat. Genet., 1996, 14, p. 199-202.
233
12. Perri F., Annese V., Pieroli A. et al. HLA antigens
and pANCA defi ne ulcerative colitis as a genetically heterogeneous
disorder. In: Ital. J. Gastroenterol. Hepatol.,
1998, 30(1), p. 56-61.
13. Leidenius M.N.K., Koskimies S.A., Kellokumpu
I.H., Hockerstedt K.A.V. HLA antigens in ulcerative colitis
and primary sclerosing cholangitis. In: Acta Path. Microbiol.
Immunol. Scandinavica, 1995, 103 (7-8), p. 519-524.
14. Masuda H., Nakamura Y., Tanaka T., Hayakawa S.
Distinct relationship between HLA-DR genes and intractability
of ulcerative colitis. In: J. Gastroenterol., 1994, 89,
p. 1957-1962.
15. Cassinotti A., Birindelli S., Clerici M. et al. HLA
and autoimmune digestive disease: a clinically oriented
review for gastroenterologist. In: Am. J. Gastroenterol.,
2009, 104, p. 195-217.
16. Fiocchi C., Susceptibility Genes and overall
pathogenesis of infl ammatory bowel disease: where do we
stand? In: Dig. Dis., 2009, 27(3), p. 226-235.
17. Schreiber S., Clinical implications of genetic fi ndings
in infl ammatory bowel disease. In: Inflammation in
the intestinal tract. Falk symposium 169, Kiev, 2009, p.
18-19.
18. Fowler E.V., Doecke J., Simms L.A. et al., AT-
G16L1 T300A shows strong association with disease subgroups
in a larg Australian IBD population: further support
for signifi cant disease heterogeneity. In: Am. J. Gastroenterol.,
2008, 103, p. 2519-2526.
19. Quinton J.F., Sendid B., Reumax D. et al., Anti-
Saccharomyces cerevisiae mannan antibodies combined
with antineutrophil cytoplasmic autoantibodies in infl ammatory
bowel disease: prevalence and diagnostic role. In:
Gut, 1998, 42, p. 788-791.
20. Marcelletti J., Moskowitz D., Stempak J et al.,
Anti-microbial antibody markers as prognostic indicators
of infl ammatory bowel disease course. In: Gastroenterol.,
2005, 128 (suppl. 4), A 305.
21. Altstock R., Shtevi A., Karban A. et al., Improved
IBD diagnosis via ELISA detecting novel antibodies:
ACCA, ALCA and AMCA. In: Gastroenterol., 2005, 128
(suppl. 4), A 303.
22. Schwarz S., Ammirati M. et al., Identifi cation of
indeterminate colitis using PANCA and ASCA. In: Gastroenterol.,
2000, 118 (suppl.2), A 1891.
23. Dotan I., New serologic markers for infl ammatory
bowel disease diagnosis. In: Dig. Dis., 2010, 28(3), p. 418-
23.
24. Genunche-Dumitrescu A., Mitrut P., Badea D.,
Badea M., The serum level of cytokines (IL-1, IL-6) and
TNF-alfa in patients with infl ammatory bowel disease. In:
Mechanisms of intestinal inflammation. Falk Workshop.
Dresden, 2007, p. A 14.
25. Atreya R., Neurath M.F., Chemokines in infl ammatory
bowel disease. In: Dig. Dis., 2010, 28(3), p. 386-
394.
26. Zeitz M., Immunoregulation: Crohn’s disease
versus ulcerative colitis. In: Inflammatory bowel disease
– Diagnostic and therapeutic strategies. Falk Symposium
154. Moscow, 2006, p. 25-26.
27. Deretic V., Links between autophagy, innate immunity,
infl ammation and Crohn’s disease. In: Dig. Dis.,
2009, 27(3), p. 246-251.
28. Rioux J.D., Xavier R.J., Taylor K.D. et al., Genome-wide
association study identifi es new susceptibility